Pure Global AI
NCT06419660Not yet recruiting

A Study in Healthy Men to Test Whether Esomeprazole Influences the Amount of BI 3000202 in the Blood

The Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of a Single Oral Dose BI 3000202 in Healthy Male Subjects (an Open-label, Randomized, Two-way Cross-over Study)
Boehringer IngelheimPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Healthy
Drug/Device/Intervention
BI 300202
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Boehringer Ingelheim
Timeline & enrollment
Phase
Phase 1
Start date
May 21, 2024
End date
Jul 02, 2024
Enrollment
16 participants
Primary outcome

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz),Maximum measured concentration of the analyte in plasma (Cmax)

Summary

The main objective of this trial is to investigate the effect of the proton pump inhibitor
 esomeprazole on the pharmacokinetics of BI 3000202 in plasma.

ICD-10 classifications
ObesitySeeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personLifestyle-related conditionMalnutrition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06419660
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06419660 through Pure Global AI's free database. This Phase 1 trial is sponsored by Boehringer Ingelheim and is currently Not yet recruiting. The study focuses on Healthy. Target enrollment is 16 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.